Hematological Malignancies | Norton Healthcare

Indication: Hematological Malignancies

A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study of Pracinostat in Combination with Azacitidine in Patients ?18 Years with Newly Diagnosed Acute Myeloid Leukemia unfit for Standard Induction Chemotherapy


Sub-indication: AML greater than 75 years old with intermidiate or unfavorable cytogenetics

Line of Therapy: treatment naive

Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: Helsinn Healthcare/Therapeutics

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.